AbbVie is in the midst of an extended move up the charts that has taken shares to new highs. As it now approaches $200, there is reason to believe that the company's share price may soon need to ...

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection. However, the shares look pricey at the moment. AbbVie is known as ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

One of the world's top biopharma companies, AbbVie (NYSE: ABBV) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality ...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 – jumping from levels of $90 then to around $195 now – vs. an increase of about 50% for the S&P 500 over this ...

You can see how EPS has changed over time in the image below (click on the chart to see the exact values). It might be well worthwhile taking a look at our free report on AbbVie's earnings ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). The chart below shows the ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other big name stocks. In early April 2024, Goldman Sachs Inc.’s data revealed that short selling ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

AbbVie's Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven's Nurtec The top-selling CGRP is Pfizer’s Nurtec, which rang up sales of $928 million last year.